BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 10415940)

  • 1. Moxonidine acting centrally inhibits airway reflex responses.
    Haxhiu MA; Dreshaj IA; McFadden CB; Erokwu BO; Ernsberger P
    Ann N Y Acad Sci; 1999 Jun; 881():372-82. PubMed ID: 10415940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. I1-imidazoline receptors and cholinergic outflow to the airways.
    Haxhiu MA; Dreshaj IA; McFadden CB; Erokwu BO; Ernsberger P
    J Auton Nerv Syst; 1998 Jul; 71(2-3):167-74. PubMed ID: 9760053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla.
    Haxhiu MA; Dreshaj I; Schäfer SG; Ernsberger P
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S1-8. PubMed ID: 7533221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine.
    Bock C; Niederhoffer N; Szabo B
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr; 359(4):262-71. PubMed ID: 10344524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of I1 imidazoline receptors in the sympathoinhibition produced by intracisternally administered rilmenidine and moxonidine.
    Szabo B; Urban R
    Arzneimittelforschung; 1997 Sep; 47(9):1009-15. PubMed ID: 9342413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of moxonidine, an I1-imidazoline receptor agonist.
    Ziegler D; Haxhiu MA; Kaan EC; Papp JG; Ernsberger P
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S26-37. PubMed ID: 8872297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. alpha(2)-adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice.
    Tolentino-Silva FP; Haxhiu MA; Waldbaum S; Dreshaj IA; Ernsberger P
    Brain Res; 2000 Apr; 862(1-2):26-35. PubMed ID: 10799665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-dependent inhibition of neuronal c-jun in the brainstem elicited by imidazoline I1 receptor activation: role in rilmenidine-evoked hypotension.
    Wang X; Li G; Abdel-Rahman AA
    Eur J Pharmacol; 2005 May; 514(2-3):191-9. PubMed ID: 15910806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits.
    Chan CK; Sannajust F; Head GA
    J Pharmacol Exp Ther; 1996 Feb; 276(2):411-20. PubMed ID: 8632304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptors involved in moxonidine-stimulated atrial natriuretic peptide release from isolated normotensive rat hearts.
    Mukaddam-Daher S; Menaouar A; Gutkowska J
    Eur J Pharmacol; 2006 Jul; 541(1-2):73-9. PubMed ID: 16774751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine.
    Chan CK; Head GA
    J Hypertens; 1996 Jul; 14(7):855-64. PubMed ID: 8818924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.
    Ernsberger P; Friedman JE; Koletsky RJ
    J Hypertens Suppl; 1997 Jan; 15(1):S9-23. PubMed ID: 9050981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxonidine inhibits excitatory inputs to airway vagal preganglionic neurons via activation of both α
    Zhou X; He D; Yan X; Chen X; Li R; Zhang G; Wang J
    Brain Res; 2020 Apr; 1732():146695. PubMed ID: 32007398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why imidazoline receptor modulator in the treatment of hypertension?
    Schäfer SG; Kaan EC; Christen MO; Löw-Kröger A; Mest HJ; Molderings GJ
    Ann N Y Acad Sci; 1995 Jul; 763():659-72. PubMed ID: 7677385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of I(1)-imidazoline receptors and alpha2-adrenoceptors in hemodynamic effects of moxonidine administration into the rostroventrolateral medulla.
    Khokhlova ON; Murashev AN; Medvedev OS
    Bull Exp Biol Med; 2001 Apr; 131(4):336-9. PubMed ID: 11550020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of alpha 2-adrenoceptors in the cardiovascular effects of moxonidine.
    Urban R; Szabo B; Starke K
    Eur J Pharmacol; 1995 Aug; 282(1-3):19-28. PubMed ID: 7498275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of moxonidine-induced increase in ANP release by atrial hypertrophy.
    Cao C; Kang CW; Kim SZ; Kim SH
    Am J Physiol Heart Circ Physiol; 2004 Jul; 287(1):H150-6. PubMed ID: 14975931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presynaptic effects of moxonidine in isolated buffer perfused rat hearts: role of imidazoline-1 receptors and alpha2-adrenoceptors.
    Schäfer U; Burgdorf C; Engelhardt A; Kurz T; Richardt G
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1163-70. PubMed ID: 12438540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.